JP Morgan Chase
KALV

JP Morgan Chase’s KalVista Pharmaceuticals KALV Stock Holding History

JP Morgan Chase’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404K Buy
22,026
+2,572
+13% +$41.5K ﹤0.01% 5150
2025
Q4 		$314K Sell
19,454
-1,305
-6% -$17.3K ﹤0.01% 5285
2025
Q3 		$253K Sell
20,759
-2,459
-11% -$34K ﹤0.01% 5390
2025
Q2 		$262K Sell
23,218
-379,286
-94% -$4.64M ﹤0.01% 5100
2025
Q1 		$4.64M Buy
402,504
+381,244
+1,793% +$3.89M ﹤0.01% 3227
2024
Q4 		$180K Sell
21,260
-1,350
-6% -$14K ﹤0.01% 5518
2024
Q3 		$262K Buy
22,610
+1,670
+8% +$21K ﹤0.01% 5283
2024
Q2 		$247K Sell
20,940
-69,620
-77% -$812K ﹤0.01% 5054
2024
Q1 		$1.07M Buy
90,560
+63,768
+238% +$850K ﹤0.01% 4298
2023
Q4 		$328K Sell
26,792
-244,149
-90% -$2.22M ﹤0.01% 5046
2023
Q3 		$2.61M Sell
270,941
-19,334
-7% -$198K ﹤0.01% 3355
2023
Q2 		$2.61M Sell
290,275
-44,034
-13% -$406K ﹤0.01% 3336
2023
Q1 		$2.63M Buy
334,309
+7,306
+2% +$54.5K ﹤0.01% 3345
2022
Q4 		$2.21M Buy
327,003
+190,809
+140% +$1.02M ﹤0.01% 3480
2022
Q3 		$1.98M Sell
136,194
-7,657
-5% -$107K ﹤0.01% 3472
2022
Q2 		$1.42M Buy
143,851
+130,427
+972% +$1.44M ﹤0.01% 3832
2022
Q1 		$198K Buy
13,424
+2,677
+25% +$38.5K ﹤0.01% 5202
2021
Q4 		$142K Buy
10,747
+1,656
+18% +$26.4K ﹤0.01% 5530
2021
Q3 		$159K Buy
9,091
+332
+4% +$6.73K ﹤0.01% 5350
2021
Q2 		$210K Buy
8,759
+425
+5% +$11.1K ﹤0.01% 5222
2021
Q1 		$214K Sell
8,334
-27,239
-77% -$716K ﹤0.01% 5120
2020
Q4 		$676K Buy
35,573
+12,293
+53% +$211K ﹤0.01% 4197
2020
Q3 		$294K Sell
23,280
-7,848
-25% -$98.1K ﹤0.01% 4204
2020
Q2 		$376K Sell
31,128
-28,237
-48% -$300K ﹤0.01% 3971
2020
Q1 		$454K Buy
59,365
+40,223
+210% +$543K ﹤0.01% 3862
2019
Q4 		$341K Buy
19,142
+15,315
+400% +$200K ﹤0.01% 4436
2019
Q3 		$44K Sell
3,827
-33,481
-90% -$541K ﹤0.01% 5229
2019
Q2 		$806K Sell
37,308
-24,754
-40% -$581K ﹤0.01% 3983
2019
Q1 		$1.78M Buy
62,062
+25,267
+69% +$548K ﹤0.01% 3413
2018
Q4 		$727K Buy
36,795
+31,183
+556% +$627K ﹤0.01% 3930
2018
Q3 		$124K Sell
5,612
-1,650
-23% -$22.3K ﹤0.01% 4871
2018
Q2 		$59K Sell
7,262
-13,678
-65% -$121K ﹤0.01% 5016
2018
Q1 		$199K Sell
20,940
-8,133
-28% -$85.1K ﹤0.01% 4373
2017
Q4 		$283K Buy
+29,073
New +$303K ﹤0.01% 4291
2016
Q1 		– Sell
-53
Closed -$3K – 4811
2015
Q4 		$3K Buy
+53
New +$2.77K ﹤0.01% 4444

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase's KALV Position: Q1 2026 in Review

JP Morgan Chase increased its KalVista Pharmaceuticals (KALV) stake by 13% in Q1 2026, buying an estimated $41.5K and bringing the position to 22,026 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #5150.

JP Morgan Chase first reported a position in KALV in Q4 2015 and has held it in 35 quarters since. The position peaked at $4.64M in Q1 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • JP Morgan Chase held 22,026 shares of KalVista Pharmaceuticals worth $404K as of Q1 2026.
  • JP Morgan Chase bought 2,572 KalVista Pharmaceuticals shares in Q1 2026, an estimated $41.5K.
  • KalVista Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5150 holding.
  • JP Morgan Chase first reported a position in KalVista Pharmaceuticals in Q4 2015 and has held it in 35 quarters since.
  • JP Morgan Chase's KalVista Pharmaceuticals position peaked at $4.64M in Q1 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.